Jana Medical narrows losses to SAR 3.3M in H1 2024

20/10/2024 Argaam Exclusive

Jana Medical Co., on track to list on Nomu-Parallel Market, narrowed its net losses to SAR 3.3 million in the first six months of 2024, compared to SAR 3.8 million a year earlier.



Financials (M)

Item 6m 2023 6m 2024 Change‬
Revenues 21.45 24.43 13.9 %
Gross Income 8.09 10.13 25.2 %
Operating Income (2.87) 0.57 119.9 %
Net Income (3.85) (3.35) 13.0 %
Average Shares 2.57 2.57 -
EPS (Riyals) (1.50) (1.30) 13.0 %

This came as the first-half revenues grew to SAR 24.4 million, from SAR 21.4 million for the same period last year.

 

The gross profit margin also rose from 38% in H1 2023 to 41% in H1 2024, along with a decrease in the ratio of cost of sales (COGS) to total revenue to 59%.

 

Besides, Jana Medical saw a decrease in the expected credit loss provision for the current period to SAR 3.7 million, compared to SAR 5.7 million in the first half of 2023.

 

Earnings before interest, taxes, depreciation, and amortization (EBITDA) for H1 2024 amounted to SAR 758,000, against a loss of SAR 2.7 million in H1 2023.

 

On the other hand, financing costs increased to SAR 4.1 million in H1 2024, compared to SAR 894,500 in the year before.

 

Jana Medical’s top line is represented in sales of consumables, medical supplies and equipment. Its products are solely sold across Saudi Arabia through the company's branches nationwide.



Current Half Annual Comparison (M)

Compared With The
Item H1 2023 H1 2024 Change‬
Revenues 21.45 24.43 13.9 %
Gross Income 8.09 10.13 25.2 %
Operating Income (2.87) 0.57 119.9 %
Net Income (3.85) (3.35) 13.0 %
Average Shares 2.57 2.57 -
EPS (Riyals) (1.50) (1.30) 13.0 %

Total shareholders’ equity, no minority interest, stood at SAR 32.91 million as of June 30, 2024, compared to SAR 26.76 million a year earlier.

 

In 2023, Jana Medical’s extraordinary general meeting (EGM) approved the board’s proposal to transform from a closed joint-stock company to a public joint-stock firm, besides floating all of the share capital on Nomu.

 

Besides, raising the issued capital from SAR 25.7 million to SAR 32.12 million has been greenlit, by way of cash shares that will be offered for public subscription in Nomu.

View More Financial Results

 

View other reports

Share Price

Jana Medical Co.
37.10
(1.70) (4.38 %)

Jana Medical Co. (JANA)

More


Financial Ratios
Current
Market Cap (M Riyal) 119.09
Enterprise Value (EV) (M) 145.49
Shares Outstanding ((M)) 3.21
Book Value (BV) ( Riyal) 14.11
Par Value ( Riyal) 10.00
Adjusted P/E (Last12) 21.99
Price/book 3.28
more


Financial results (Million)

Period Revenues Change Gross Income Change Operating Income Change
H1 2015 - - - - - -
H2 2015 - - - - - -
H1 2016 - - - - - -
H2 2016 - - - - - -
H1 2017 - - - - - -
H2 2017 - - - - - -
H1 2018 - - - - - -
H2 2018 - - - - - -
H1 2019 - - - - - -
H2 2019 - - - - - -
H1 2020 - - - - - -
H2 2020 - - - - - -
H1 2021 - - - - - -
H2 2021 - - - - - -
H1 2022 - - - - - -
H2 2022 - - - - - -
H1 2023 21.45 - 8.09 - (2.87) -
H2 2023 39.91 - 17.70 - 15.54 -
H1 2024 24.43 13.9 % 10.13 25.2 % 0.57 119.9 %


Profit Performance (Million)

Period Net Income Change EPS(Riyal) Extraordinary Income/Expense Net Profit Before Unusual Items EPS Before XO Items
H1 2015 - - - - - -
H2 2015 - - - - - -
H1 2016 - - - - - -
H2 2016 - - - - - -
H1 2017 - - - - - -
H2 2017 - - - - - -
H1 2018 - - - - - -
H2 2018 - - - - - -
H1 2019 - - - - - -
H2 2019 - - - - - -
H1 2020 - - - - - -
H2 2020 - - - - - -
H1 2021 - - - - - -
H2 2021 - - - - - -
H1 2022 - - - - - -
H2 2022 - - - - - -
H1 2023 (3.85) - (1.50) - (3.85) (1.50)
H2 2023 9.26 - 3.60 - 9.26 3.60
H1 2024 (3.35) 13.0 % (1.30) - (3.35) (1.30)

Profitability

Period Gross Margin OIBDA Margin Net Margin Before Unusual Items
H1 2015 - - -
H2 2015 - - -
H1 2016 - - -
H2 2016 - - -
H1 2017 - - -
H2 2017 - - -
H1 2018 - - -
H2 2018 - - -
H1 2019 - - -
H2 2019 - - -
H1 2020 - - -
H2 2020 - - -
H1 2021 - - -
H2 2021 - - -
H1 2022 - - -
H2 2022 - - -
H1 2023 - - -
H2 2023 42.03 % 21.28 % 8.82 %
H1 2024 43.25 % 25.65 % 9.19 %


Per Share Data (Riyal)

Compared With The
Period Shares Outstanding (M) EPS (Riyal) Adjusted EPS (Riyal) Book Value (BV)
H1 2015 - - - -
H2 2015 - - - -
H1 2016 - - - -
H2 2016 - - - -
H1 2017 - - - -
H2 2017 - - - -
H1 2018 - - - -
H2 2018 - - - -
H1 2019 - - - -
H2 2019 - - - -
H1 2020 - - - -
H2 2020 - - - -
H1 2021 - - - -
H2 2021 - - - -
H1 2022 - - - -
H2 2022 - - - -
H1 2023 2.57 - - 10.41
H2 2023 2.57 2.11 2.11 14.11
H1 2024 2.57 2.30 2.30 12.81

Multiple Ratios (End of Period Price)

Compared With The
Period P/E Adjusted P/E Price/book
H1 2015 - - -
H2 2015 - - -
H1 2016 - - -
H2 2016 - - -
H1 2017 - - -
H2 2017 - - -
H1 2018 - - -
H2 2018 - - -
H1 2019 - - -
H2 2019 - - -
H1 2020 - - -
H2 2020 - - -
H1 2021 - - -
H2 2021 - - -
H1 2022 - - -
H2 2022 - - -
H1 2023 - - -
H2 2023 - - -
H1 2024 - - -

Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
loader Train
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Popular Links

Quick Links

Join Us

Argaam.com Copyright © 2024, Argaam Investment, All Rights Reserved
Call Request